Short-term Efficacy and Safety of Lurasidone Versus Placebo in Antipsychotic-Naïve Vs. Previously Treated Adolescents with an Acute Exacerbation of Schizophrenia

Overview

Journal Eur Psychiatry

Publisher Cambridge University Press

Specialty Psychiatry

Date 2022 Mar 24

PMID 35322769

Authors

Christoph U Correll

Michael Tocco

Jay Hsu

Robert Goldman

Andrei Pikalov

Affiliations

Soon will be listed here.

Citing Articles

Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence.

Mora F, Gomez Sanchez-Lafuente C, De Iceta M, Roset C, Cardenas A, Perez D Front Psychiatry. 2025; 15:1506142.

PMID: 40013022 PMC: 11862477. DOI: 10.3389/fpsyt.2024.1506142.

Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel.

Bernardo M, Marsa M, Gonzalez-Pinto A, Carrasco M, Perez Sola V, Saiz P Neurol Ther. 2025; 14(1):85-98.

PMID: 39760831 PMC: 11762036. DOI: 10.1007/s40120-024-00700-y.

Negative symptoms in children and adolescents with early-onset psychosis and at clinical high-risk for psychosis: systematic review and meta-analysis.

Salazar de Pablo G, Catalan A, Serrano J, Pedruzo B, Alameda L, Sandroni V Br J Psychiatry. 2023; 223(1):282-294.

PMID: 37194556 PMC: 10331322. DOI: 10.1192/bjp.2022.203.

Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.

Ricci V, Martinotti G, de Berardis D, Maina G Int J Environ Res Public Health. 2022; 19(23).

PMID: 36498129 PMC: 9737174. DOI: 10.3390/ijerph192316057.

References

Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane J . Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013; 147(1):95-102. DOI: 10.1016/j.schres.2013.03.013. View

De Hert M, Dobbelaere M, Sheridan E, Cohen D, Correll C . Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011; 26(3):144-58. DOI: 10.1016/j.eurpsy.2010.09.011. View

Toftdahl N, Nordentoft M, Hjorthoj C . Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study. Soc Psychiatry Psychiatr Epidemiol. 2015; 51(1):129-40. DOI: 10.1007/s00127-015-1104-4. View

Zhang C, Wang Q, Ni P, Deng W, Li Y, Zhao L . Differential Cortical Gray Matter Deficits in Adolescent- and Adult-Onset First-Episode Treatment-Naïve Patients with Schizophrenia. Sci Rep. 2017; 7(1):10267. PMC: 5579015. DOI: 10.1038/s41598-017-10688-1. View

Azad M, Shoesmith W, Al Mamun M, Abdullah A, Naing D, Phanindranath M . Cardiovascular diseases among patients with schizophrenia. Asian J Psychiatr. 2016; 19:28-36. DOI: 10.1016/j.ajp.2015.11.012. View

Dipasquale S, Pariante C, Dazzan P, Aguglia E, McGuire P, Mondelli V . The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 2012; 47(2):197-207. DOI: 10.1016/j.jpsychires.2012.10.005. View

Torres U, Duran F, Schaufelberger M, Crippa J, Louza M, Sallet P . Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness. Neuroimage Clin. 2016; 12:1-15. PMC: 4910144. DOI: 10.1016/j.nicl.2016.06.002. View

Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M . Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2007; 68(11):1763-74. DOI: 10.4088/jcp.v68n1116. View

Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey P, Kopala L . Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005; 162(5):947-53. DOI: 10.1176/appi.ajp.162.5.947. View

10.

Green A, Lieberman J, Hamer R, Glick I, Gur R, Kahn R . Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006; 86(1-3):234-43. DOI: 10.1016/j.schres.2006.06.021. View

11.

Correll C, Findling R, Tocco M, Pikalov A, Deng L, Goldman R . Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. CNS Spectr. 2020; 27(1):118-128. DOI: 10.1017/S1092852920001893. View

12.

Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C . The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019; 6(8):675-712. DOI: 10.1016/S2215-0366(19)30132-4. View

13.

Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J . Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(6):829-36. DOI: 10.4088/JCP.08m04905. View

14.

De Hert M, Detraux J, van Winkel R, Yu W, Correll C . Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8(2):114-26. DOI: 10.1038/nrendo.2011.156. View

15.

Correll C . Safety and tolerability of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry. 2011; 72(8):e26. DOI: 10.4088/JCP.9101tx5c. View

16.

Posner K, Brown G, Stanley B, Brent D, Yershova K, Oquendo M . The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12):1266-77. PMC: 3893686. DOI: 10.1176/appi.ajp.2011.10111704. View

17.

Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali A . Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013; 145(1-3):101-9. DOI: 10.1016/j.schres.2013.01.009. View

18.

Immonen J, Jaaskelainen E, Korpela H, Miettunen J . Age at onset and the outcomes of schizophrenia: A systematic review and meta-analysis. Early Interv Psychiatry. 2017; 11(6):453-460. PMC: 5724698. DOI: 10.1111/eip.12412. View

19.

Correll C, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P . Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017; 16(2):163-180. PMC: 5428179. DOI: 10.1002/wps.20420. View

20.

Cunningham Owens D, Johnstone E, Miller P, Macmillan J, Crow T . Duration of untreated illness and outcome in schizophrenia: test of predictions in relation to relapse risk. Br J Psychiatry. 2010; 196(4):296-301. DOI: 10.1192/bjp.bp.109.067694. View